Pradaxa

📋 Product Overview Table

🧬 What is Pradaxa (Dabigatran Etexilate)?

Pradaxa is an oral anticoagulant that contains the active ingredient Dabigatran Etexilate. Manufactured by Boehringer Ingelheim India Pvt. Ltd, it is widely prescribed for the prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation, as well as for the treatment and prevention of deep vein thrombosis (DVT) and pulmonary embolism (PE).

Pradaxa belongs to a class of drugs known as direct thrombin inhibitors, offering a convenient alternative to traditional anticoagulants like warfarin, without the need for routine INR monitoring. It is available in three strengths to support individualized dosing based on patient risk, renal function, and therapeutic need.

🎬 Educational Video Placeholder

🩺 Doctor’s Expert Commentary

Dr. Anjali Kumar, MD – Cardiology:
“Dabigatran has transformed the management of stroke prevention in atrial fibrillation. Its fixed dosing, predictable pharmacokinetics, and lack of dietary interaction make it a preferred choice in modern anticoagulation.”

💉 Dosage & Administration

⚠️ Side Effects, Warnings & Storage

• Common Side Effects: Gastritis, bleeding, nausea, indigestion
• Serious Risks: Major bleeding, especially in elderly or renal impairment
• Drug Interactions: Avoid concurrent use with other anticoagulants, NSAIDs
• Storage: Keep capsules in original blister pack, away from moisture and heat

🌍 Global Availability

🔗 Related Indian Alternatives (Same Therapeutic Class)

📚 Trusted Medical References

• FDA – Dabigatran Label
• NHS – Anticoagulants
• Drugs.com – Pradaxa Info
• WHO – Essential Medicines List

⚠️ Medical Disclaimer
This information is intended for educational use only. Please consult a licensed physician for diagnosis and treatment before starting or stopping any medication.